<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The cytokine interleukin 6 (IL-6) is an essential regulator of the <z:hpo ids='HP_0011009'>acute</z:hpo> phase response associated with insulin-resistant states including type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Three polymorphisms at positions -597, -572, and -174 of the IL6 promoter have been reported to influence IL6 transcription </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to investigate whether the IL6 promoter polymorphisms were associated with features of the WHO-defined <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and related quantitative traits in 7,553 Caucasian Danes </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Using analysis of PCR-generated primer extension products by mass spectrometry we examined -597 G/A, -572 G/C, and -174 G/C IL6 variants in the population-based Inter99 study cohort of middle-aged people (n=6,164) and in a group of type 2 diabetic patients (n=1,389) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The -174 G/C and -597 G/A polymorphisms were in strong linkage disequilibrium (R(2)=0.95) </plain></SENT>
<SENT sid="5" pm="."><plain>In the Inter99 cohort the -174 G-allele was associated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (p&lt;0.02) and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> (p&lt;0.007) whereas the C-allele of the -572 polymorphism was associated with increased serum insulin release during an OGTT (p&lt;0.0005) </plain></SENT>
<SENT sid="6" pm="."><plain>Composite genotype or haplotype analyses of <z:hpo ids='HP_0000001'>all</z:hpo> 3 IL6 promoter variants showed associations with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (p&lt;0.002), <z:hpo ids='HP_0001513'>obesity</z:hpo> (p&lt;0.02), and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (p&lt;0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The present studies suggest that single-nucleotide polymorphisms and composite genotypes or haplotypes of the IL6 promoter may be associated with several features of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in Caucasians </plain></SENT>
</text></document>